FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2554934447> ?p ?o ?g. }

• W2554934447 abstract "Abstract Abstract 5079 Background Epstein-Barr virus (EBV) is associated with a number of human malignancies, including a variety of lymphomas, post-transplant lymphoproliferative disorder, and nasopharyngeal carcinoma. EBV viral load can be measured in peripheral blood by commercially available PCR assays. We seek to establish the correlation of EBV viral load with clinical disease activity in these malignancies. Methods We prospectively enrolled patients with radiographically measurable malignancies of any of the above-mentioned types, with preference for enrollment of subtypes known to be strongly EBV-associated. A total of 65 patients signed consent, and 57 (67% newly diagnosed, 28% pretreated, 5% unknown treatment) were enrolled after fulfillment of inclusion and exclusion criteria. A 6-primer quantitative PCR panel was used, testing for EBER, LMP and EBNA both in patient plasma (P) and in whole blood cells (WB). Patients with detectable EBV PCR at baseline with any of the 6 assays were followed longitudinally as they underwent therapy. Disease status (stable/response/progression/CR) was determined by standard clinical/radiological assessments, and was correlated with EBV viral load. Results Of 57 enrolled patients, 34 (60%) had detectable EBV viral load by at least one of the 6 assays of the PCR panel. EBNA-WB, EBER-WB, and EBNA-P were the EBV assays most likely to be positive at baseline (97%, 79% and 71% respectively), with median viral loads of 650 (range 100–131,000), 200 (100-55,800) and 450 (100-134,000) copies/ml respectively. Prevalence of detectable EBV viral load at baseline varied between different malignancies (‘n' for each in brackets) – 100% for PTLD(2) and AITL(6), 75% for nasopharyngeal carcinoma(12), 63% for Hodgkin disease(8), 60% for CTCL(5), 50% for DLBCL(4), Burkitt's lymphoma(2), anaplastic TCL(4), NK/T cell lymphoma(4), 33% for PTCL(3), and 0% for follicular lymphoma(3). LMP immunohistochemical staining and EBER in-situ hybridization were performed (based on tissue availability) on samples from 63% of enrolled patients. EBV was detected in 64% of tested tissue samples. Of tissue EBV positive patients, 87% had detectable blood EBV PCR. Notably, even in tissue EBV negative patients, 38% had detectable blood PCR. Longitudinally measured viral loads were available for 27 of 34 EBV PCR positive patients, with a median of 3 tests (range 2–7) over a period of 4 months (range 0.3–14.9 months). Reduction of plasma EBV viral load to 200 copies/ml or less in the course of treatment had the strongest correlation with achievement of clinical CR (Spearman's rho 0.78, p<0.001) with the following test characteristics: PPV 87%, NPV 100%, area under ROC curve 93%. Conclusion More than half of our patients with a variety of lymphomas, PTLD and nasopharyngeal carcinoma had detectable peripheral blood EBV PCR. Most patients with tissue EBV positivity had a detectable blood viral load, but, surprisingly, more than a third of tissue EBV negative patients also had a detectable viral load, arguing for a potential role for routine blood EBV PCR testing even in the absence of tissue EBV positivity. Quantitative EBV PCR had a statistically significant correlation with clinical disease activity, and achievement of plasma EBV viral load of 200 copies/ml or less had an excellent predictive value for achievement of clinical CR. We recommend further trials exploring the role of EBV PCR in guiding duration and number of cycles of chemotherapy, and potentially using EBV PCR as a modality for early detection of relapse. Disclosures: Mato: Celgene: Speakers Bureau; Milennium: Speakers Bureau. Arnoldi:ViraCor: Employment." @default.
• W2554934447 created "2016-11-30" @default.
• W2554934447 creator A5016205416 @default.
• W2554934447 creator A5022384270 @default.
• W2554934447 creator A5022496922 @default.
• W2554934447 creator A5025991750 @default.
• W2554934447 creator A5029801761 @default.
• W2554934447 creator A5031272756 @default.
• W2554934447 creator A5051904819 @default.
• W2554934447 creator A5080630441 @default.
• W2554934447 creator A5083072418 @default.
• W2554934447 creator A5085236492 @default.
• W2554934447 creator A5088286702 @default.
• W2554934447 creator A5088834763 @default.
• W2554934447 date "2010-11-19" @default.
• W2554934447 modified "2023-10-01" @default.
• W2554934447 title "Clinical Trial of a Multitarget EBV PCR Panel In Patients with EBV Positive Malignancies: Correlation of Peripheral Blood EBV Viral Load with Disease Activity" @default.
• W2554934447 doi "https://doi.org/10.1182/blood.v116.21.5079.5079" @default.
• W2554934447 hasPublicationYear "2010" @default.
• W2554934447 type Work @default.
• W2554934447 sameAs 2554934447 @default.
• W2554934447 citedByCount "0" @default.
• W2554934447 crossrefType "journal-article" @default.
• W2554934447 hasAuthorship W2554934447A5016205416 @default.
• W2554934447 hasAuthorship W2554934447A5022384270 @default.
• W2554934447 hasAuthorship W2554934447A5022496922 @default.
• W2554934447 hasAuthorship W2554934447A5025991750 @default.
• W2554934447 hasAuthorship W2554934447A5029801761 @default.
• W2554934447 hasAuthorship W2554934447A5031272756 @default.
• W2554934447 hasAuthorship W2554934447A5051904819 @default.
• W2554934447 hasAuthorship W2554934447A5080630441 @default.
• W2554934447 hasAuthorship W2554934447A5083072418 @default.
• W2554934447 hasAuthorship W2554934447A5085236492 @default.
• W2554934447 hasAuthorship W2554934447A5088286702 @default.
• W2554934447 hasAuthorship W2554934447A5088834763 @default.
• W2554934447 hasConcept C126322002 @default.
• W2554934447 hasConcept C142462285 @default.
• W2554934447 hasConcept C203014093 @default.
• W2554934447 hasConcept C2522874641 @default.
• W2554934447 hasConcept C2778997737 @default.
• W2554934447 hasConcept C2781375147 @default.
• W2554934447 hasConcept C509974204 @default.
• W2554934447 hasConcept C71924100 @default.
• W2554934447 hasConcept C90924648 @default.
• W2554934447 hasConceptScore W2554934447C126322002 @default.
• W2554934447 hasConceptScore W2554934447C142462285 @default.
• W2554934447 hasConceptScore W2554934447C203014093 @default.
• W2554934447 hasConceptScore W2554934447C2522874641 @default.
• W2554934447 hasConceptScore W2554934447C2778997737 @default.
• W2554934447 hasConceptScore W2554934447C2781375147 @default.
• W2554934447 hasConceptScore W2554934447C509974204 @default.
• W2554934447 hasConceptScore W2554934447C71924100 @default.
• W2554934447 hasConceptScore W2554934447C90924648 @default.
• W2554934447 hasLocation W25549344471 @default.
• W2554934447 hasOpenAccess W2554934447 @default.
• W2554934447 hasPrimaryLocation W25549344471 @default.
• W2554934447 hasRelatedWork W1491144410 @default.
• W2554934447 hasRelatedWork W2016785136 @default.
• W2554934447 hasRelatedWork W2105017682 @default.
• W2554934447 hasRelatedWork W2111299712 @default.
• W2554934447 hasRelatedWork W2116721927 @default.
• W2554934447 hasRelatedWork W2117953351 @default.
• W2554934447 hasRelatedWork W2187156959 @default.
• W2554934447 hasRelatedWork W2340557175 @default.
• W2554934447 hasRelatedWork W2409613890 @default.
• W2554934447 hasRelatedWork W2470764101 @default.
• W2554934447 hasRelatedWork W2561599799 @default.
• W2554934447 hasRelatedWork W2585789348 @default.
• W2554934447 hasRelatedWork W2592926538 @default.
• W2554934447 hasRelatedWork W2594796021 @default.
• W2554934447 hasRelatedWork W2611638477 @default.
• W2554934447 hasRelatedWork W2972174027 @default.
• W2554934447 hasRelatedWork W3030783896 @default.
• W2554934447 hasRelatedWork W3032183474 @default.
• W2554934447 hasRelatedWork W3127107032 @default.
• W2554934447 hasRelatedWork W52999006 @default.
• W2554934447 isParatext "false" @default.
• W2554934447 isRetracted "false" @default.
• W2554934447 magId "2554934447" @default.
• W2554934447 workType "article" @default.